60
Participants
Start Date
May 8, 2025
Primary Completion Date
February 29, 2028
Study Completion Date
April 30, 2028
Targeted CEA CAR-T
Subjects meeting the transfusion criteria will receive pre-treatment, which is as follows: fludarabine 25mg/m2/d×3day and cyclophosphamide 300mg/m2/d×3day, and intravenous CEA CAR-T therapy after 1-2 days of rest
Targeted CEA CAR-T
Subjects meeting the reinfusion criteria will receive pre-treatment with fludarabine 25mg/m2/d×3day and cyclophosphamide 300mg/m2/d×3day, rest for 1-2 days, and intraperitoneal reinfusion targeted CEA CAR-T therapy
RECRUITING
General Hospital of Eastern Theater Command, Nanjing
Chongqing Precision Biotech Co., Ltd
INDUSTRY